Sign in →

Test Code CDAU7 Drug Abuse Survey with Confirmation, Panel 9, Random, Urine

Reporting Name

Confirmed Drug Abuse Panel 9, U

Useful For

Detecting drug abuse involving, amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, methadone, opiates, phencyclidine, and tetrahydrocannabinol

 

This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Urine


Advisory Information


For situations where chain-of-custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody testing, order CDA7X / Drug Abuse Survey with Confirmation, Panel 9, Chain of Custody, Urine.

Additional Testing Requirements


If urine creatinine is required or adulteration of the sample is suspected, the following test should be requested, ADULT / Adulterants Survey, Urine. For additional information, please refer to ADULT / Adulterants Survey, Urine.

Specimen Required


Supplies: Urine Container, 60 mL (T313)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 60-mL urine bottle

Specimen Volume: 30 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Submit 30 mL in 1 plastic bottle.

3. No preservative.

Additional Information:

1. No specimen substitutions.

2. Additional drug panels and specific requests are available. Call 800-533-1710 or 507-266-5700.

3. Submitting less than 30 mL will compromise our ability to perform all necessary testing.


Specimen Minimum Volume

15 mL

Testing Algorithm

Testing begins with screening tests for alcohol and drugs of abuse. Positives are confirmed and quantitated by definitive methods (gas chromatography-flame ionization detector for ethanol; gas chromatography-mass spectrometry for barbiturates, benzodiazepines, cocaine and metabolites, methadone, phencyclidine, and tetrahydrocannabinol metabolite) at an additional charge. Amphetamines and opiates that screen positive will be quantified with liquid chromatography-tandem mass spectrometry at an additional charge.

Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 7 days
  Frozen  14 days

Reference Values

Negative

Screening cutoff concentrations

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Benzodiazepines: 100 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Ethanol: 10 mg/dL

Methadone metabolite: 300 ng/mL

Opiates: 300 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Day(s) and Time(s) Performed

Monday through Saturday

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

80307

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CDAU7 Confirmed Drug Abuse Panel 9, U 87428-9

 

Result ID Test Result Name Result LOINC Value
30909 Alcohol 34180-0
2573 Amphetamines 16369-1
2574 Barbiturates 70155-7
2575 Benzodiazepines 16195-0
21652 Cocaine 19360-7
4435 Methadone metabolite 16246-1
2577 Opiates 18390-5
2578 Phencyclidine 18392-1
2664 Tetrahydrocannabinol 19416-7
20672 Chain of Custody 77202-0

Clinical Reference

1. Physician's Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006

2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006

3. Langman LJ, Bechtel L, Holstege CP. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. Chapter 35. WB Saunders Co, 2011, pp 1109-1188

Method Description

The amphetamines, barbiturates, benzodiazepines, cocaine, methadone metabolite, opiates, phencyclidine, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution (KIMS) as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.

 

ADH

Ethyl alcohol + NAD+ -----------------> acetaldehyde + NADH + H+

 

Analytic Time

Same day/1 day

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Method Name

CDAU7: Alcohol Screened by an Enzymatic Assay/All Others Screened by Immunoassay

ETOH: Gas Chromatography-Flame Ionization Detector (GC-FID)

Forms

If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen. 

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
OPATU Opiate Confirmation, U Yes No
AMPHU Amphetamines Confirmation, U Yes No
BARBU Barbiturates Confirmation, U Yes No
COKEU Cocaine and metabolite Conf, U Yes No
ETOH Ethanol, U No No
MTDNU Methadone Confirmation, U Yes No
PCPU Phencyclidine Confirmation, U Yes No
THCU Carboxy-THC Confirmation, U Yes No
BNZU Benzodiazepines Confirmation, U Yes No

Secondary ID

81410